Trial · NCT00844298
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00844298, Phase 2, Completed, Asan Medical Center; results first posted 2015-09-07
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia. Trials, record NCT00844298. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00844298
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- NCT number
- NCT00844298
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 91 participants, actual
- Lead sponsor
- Asan Medical Center
- Conditions
- Leukemia
- Interventions
- Nilotinib+mVPD
- First posted
- 2009-02-16
- Last updated
- 2015-09-07
- Results first posted
- 2015-09-07
- Limitations and caveats
- The limitation of the current study was that this study was not performed in a randomized comparative way, and the advantages of nilotinib over other TKIs were not definitely demonstrated.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of Patients Achieving Hematologic and Molecular Complete Remission (CR) After Induction Therapy | 1 month | approximate time: at the recovery of cytopenia |
| Secondary | Disease(Relapse)-Free Survival | 2 years | |
| Secondary | Overall Survival | 2 years |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Proportion of Patients Achieving Hematologic and Molecular Complete Remission (CR) After Induction Therapy | 1 month | percentage of analyzable subjects | NUMBER | |
| SECONDARY | Disease(Relapse)-Free Survival | 2 years | |||
| SECONDARY | Overall Survival | 2 years |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Patients Achieving Hematologic and Molecular Complete Remission (CR) After Induction Therapy | Nilotinib+mVPD | 91 | percentage of analyzable subjects |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Nilotinib+mVPD | 91 | |
| Overall Study | COMPLETED | Nilotinib+mVPD | 91 | |
| Overall Study | NOT COMPLETED | Nilotinib+mVPD | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Jaundice | Hepatobiliary disorders | Nilotinib+mVPD | 79 | 91 | 214 |
| serious | Febrile neutropenia | Infections and infestations | Nilotinib+mVPD | 18 | 91 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Nilotinib+mVPD | ||
| Total, other adverse events | Nilotinib+mVPD | 79 | 91 |
| Total, serious adverse events | Nilotinib+mVPD | 18 | 91 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 26065651 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00844298
GET https://conductscience.org/api/trials/v1/NCT00844298/registered